SMARCB1 and central nervous system cancer: Recurrent alterations occurring in ≥75% of tumors (with ≥2 sequenced) in specific DNA methylation classes included histone 3 K27M in DMG, K27 (27/27), H3F3A G34R/V in HGG, G34 (11/11), IDH1 in gliomas, IDH-mutant (7/7), BCOR ITD in CNS, BCOR (6/6), SMARCB1 in ATRT, TYR (6/8), DICER1 in primary intracranial DICER1-mutant sarcomas (2/2), NF2 in spinal EPN (2/2) and TSC1 in SEGA (2/2).